warrants Progenity Enters $25M Private Placement The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72. OpGen Enters $25M Direct Offering Agreement A single healthcare-focused investor will purchase 2.78 million shares of common stock, 5.55 million prefunded warrants, and an additional 4.17 million shares of common stock. OpGen Prices $9.4M Stock, Warrant Offering OpGen said it intends to use the proceeds of the offering to complete its acquisition of German molecular diagnostics firm Curetis, among other things. OpGen Plans $10.4M Stock, Warrant Sale The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators. Fulgent Genetics to Offer $75M of Securities The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series. Feb 8, 2019 Biocept Prices $7.5M Public Offering of Stocks, Warrants Dec 19, 2018 Biocept Reduces Number of Shares, Warrants for Public Offering Jul 27, 2018 OncoCyte Eyes $3.6M Raise in Securities Offering Jul 11, 2018 Biocept Prices Subscription Rights to Purchase $25M of Securities Nov 13, 2017 Precipio Completes Public Offering, Raises $2.7M Jul 25, 2017 OncoCyte Nets $5.7M From Exercise of Warrants Jun 29, 2017 OpGen Increases Public Offering to Up to $15.6M Jun 7, 2017 Interpace Files to Raise $10.5M Feb 21, 2017 OncoCyte Raises $2M Through Early Warrant Exercise Jan 3, 2017 Interpace Eyes $3.7M in Proceeds from Securities Purchase Deal May 20, 2016 Cancer Genetics Launches $5M Private Financing Dec 29, 2015 Great Basin Inks Deal to Sell $20.5M in Securities to Institutional Investors Sep 16, 2015 Great Basin Shares Fall on Plans to Restructure Warrants May 15, 2015 Nanosphere Closes $4.4M Financing Round, $30M Debt Facility Mar 4, 2015 Transgenomic Closes Public Offering of Stock, Warrants Mar 3, 2015 Great Basin Completes Follow-on Public Offering, Raises $20.5M in Net Proceeds Feb 13, 2015 CombiMatrix to Raise $4.9M from Direct Offering Feb 9, 2015 Biocept Amends Offering for up to $23M in Stock, Warrants Feb 3, 2015 GeneNews to Receive C$1.4M from Exercise of Warrants Jan 20, 2015 Great Basin Files for Public Offering of Stock, Warrants Load More Breaking News Sequencing Study Uncovers MERS-Related Coronavirus in Swiss Bats Angstrom Bio Raises $3M in Private Financing Eagle Biosciences, Genetic Analysis Ink Distribution Agreement for Gut Microbiota Test Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel The Scan CDC Calls Delta "Variant of Concern" CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern." From FDA to Venture Capital Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post. Consent Questions Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles. Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.